Mechanistically, RING1B associates with specific cPRC1 components that are recruited to enhancers containing estrogen receptor alpha (ERα) in ER+ cells, and to BRD4-containing enhancers in triple-negative breast cancer (TNBC) cells. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.